# NUF2 and NEK2 promote malignant progression of gallbladder cancer by remodeling the extracellular matrix

## TL;DR

This study identifies NUF2 and NEK2 as key genes promoting gallbladder cancer progression by altering the extracellular matrix.

## Contribution

The study discovers NUF2 and NEK2 as novel hub genes involved in gallbladder cancer progression through ECM remodeling.

## Key findings

- NUF2 and NEK2 are overexpressed in gallbladder cancer tumor tissues.
- These genes promote cancer cell proliferation and ECM remodeling.
- ECM-related processes are significantly enriched in differentially expressed genes.

## Abstract

Gallbladder cancer (GBC) ranks as the most common malignant tumor of the biliary tract, which has been characterized by late diagnosis, low excisional rate, and poor prognosis. Recent studies exploring the roles of malignant progression-associated genes in GBC remain limited. Our study aims to identify significant hub genes involved in its pathogenesis, which may serve as novel potential therapeutic targets for GBC. Here, we employed RNA-seq analysis to identify differentially expressed genes (DEGs) of seven GBC samples and five matched adjacent samples. After screening the DEGs in clinical sequencing data and GSE139682, we further obtained 549 genes with consistent expression trends in two datasets, including 155 upregulated and 394 downregulated genes. Gene Ontology (GO) enrichment analysis revealed that these genes were significantly enriched in extracellular matrix (ECM)-related processes, such as organization, structure, and composition, which hint to us that remodeling of ECM may be the main driving factor for the malignant progression of GBC. In addition, we screened 17 candidate hub genes through protein-protein interaction (PPI) network analysis and Cytoscape, subsequent GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses showed that the remodeled ECM mainly functions by affecting cell division. Moreover, we found that NEK2 and NUF2 were overexpressed in GBC tumor tissues and validated their function in the pro-proliferation of GBC cells. Our results highlight that NEK2 and NUF2 may be hub genes promoting the malignant progression of GBC and are expected to be reliable new therapeutic targets for GBC.

Graphical Abstract